U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07915947) titled 'LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study' on Oct. 29.
Brief Summary: This Phase 1, single-center, open-label, randomized, parallel-group study will evaluate the effect of itraconazole on the PK of LTG-321 and its metabolite(s), and the safety and tolerability of LTG-321 administered alone and in combination with itraconazole, in healthy participants.
Study Start Date: Dec. 04
Study Type: INTERVENTIONAL
Condition:
PK Drug-drug Interaction Study
Intervention:
DRUG: LTG-321
LTG-321 is a novel, orally bioavailable, small molecule NaV1.8 inhibitor being developed as a non-opioid analgesic product
DRUG: Itraconazole...